WO2015155629A1

WO2015155629A1 - Saturation method of a drug for dental

Info

Publication number: WO2015155629A1
Application number: PCT/IB2015/052352
Authority: WO
Inventors: Ajay Reddy MAREDDY; Harivinder Reddy KONYALA; Swetha Reddy MOOTHUKPALLY
Original assignee: Individual
Current assignee: Individual
Priority date: 2014-04-11
Filing date: 2015-03-31
Publication date: 2015-10-15
Anticipated expiration: 2016-10-11

Abstract

A saturation method of a drug for dental comprises obturation of one or more pulp canals attained with blend of copolymer composition comprising a poly-lactic acid and a poly-glycolic acid, inserting a plurality of non medicated PLGA cones into an infected canal of one or more tooth up to a reliable length, the cone incorporated with various medicaments used for constant controlled drug release system in one or more periapicalyinfected tooth.

Description

SATURATION METHOD OF A DRUG FOR DENTAL

TECHNICAL FIELD

[001] The present disclosure is generally related to the field of endodontics, newer obturation method of primary teeth. More particularly the present disclosure relates to an infected tooth medicated using a cone molded with Poly-Lactic Acid and Poly-Glycolic Acid.

BACKGROUND

[002] Pulpitis is one of the most common infections that can be notified in any person irrespective of the age. The method used to treat infected pulp is specified as Pulp therapy. Pulp therapy aims in cleaning and shaping of root canal followed by obturation. Pulp therapy for deciduous teeth aims to retain treated deciduous tooth in a symptom free state until it is lost naturally during the transition from primary to permanent dentition. Significance of obturation relies on prevention of under filling and overzealous filling, which may cause biologic irritation to the surrounding tissue. Conventionally, there are few methods that are used to medicate the tooth suffering with the periapical infection. These methods include bulk of materials pushed blindly into prepared canals which may harm permanent teeth.

[003] Conventionally, Zinc oxide Eugenol and metapex paste are the common root canal filling materials recommended for primary teeth. However they have certain disadvantages like slow resorption, irritation to the periapical tissues, necrosis of bone and cementum and alter the path of eruption of succedaneous tooth.

[004] In the light of aforementioned discussion there exists a need of a newer ideal filling material for normal primary teeth and saturation method of a drug release for periapical infected teeth.

BRIEF SUMMARY

[005] The following presents a simplified summary of the disclosure in order to provide a basic understanding to the reader. This summary is not an extensive overview of the disclosure and it does not identify key/critical elements of the invention or delineate the scope of the invention. Its sole purpose is to present some concepts disclosed herein in a simplified form as a prelude to the more detailed description that is presented later.

[006] A more complete appreciation of the present disclosure and the scope thereof can be obtained from the accompanying drawings which are briefly summarized below and the following detailed description of the presently preferred embodiments.

[007] An exemplary objective of the present disclosure is to medicate the periapical infected tooth with a medicated cone molded with PLGA copolymer blend, while non infected tooth obtruated with non medicated PLGA cone.

[008] Another exemplary embodiment of the present disclosure is directed towards a method of saturation of a control drug release in endodontics. According to a first aspect, the method comprises obturation of tooth attained with a blend of copolymer composition comprising a Poly- Lactic Acid; and a Poly- Glycolic Acid and inserting a cone molded with copolymer composition into prepared canals up to a reliable length. Another aspect regarding infected canal of one or more tooth, whereby the cone incorporated with various medicaments used for constant controlled drug release system for reduction of infection and restoring to healthy status .

[009] According to a first aspect, the method comprises a step of metabolizing the copolymer composition with its biocompatible; and bioresorbable property, a step of excluding a toxic effect of the cone to the apical tissue of the one or more tooth with the biocompatibility property of the copolymer composition and a step of attaining metabolism in vivo through hydrolysis into alpha hydraulic acids present within the body.

[0010] According to a first aspect, the method comprises a step of inserting the cone of reliable length into the one or more tooth attained using radiography and a step of exhibiting proper operative assessment by visualization of Radio-opacity using radiographs. BRIEF DESCRIPTION OF DRAWINGS

[0011] Other objects and advantages of the present invention will become apparent to those skilled in the art upon reading the following detailed description of the preferred embodiments, in conjunction with the accompanying drawings, wherein like reference numerals have been used to designate like elements, and wherein:

[0012] FIG. 1A is a diagram illustrating an exemplary arrangement of cone molded with copolymer composition.

[0013] FIG. IB is a diagram illustrating an exemplary arrangement of cone inserted into the root canal of the tooth

[0014] FIG. 2 A is a diagram illustrating an exemplary arrangement of decay formed over the tooth with periapical infection.

[0015] FIG. 2B is a diagram illustrating an exemplary arrangement of medicated copolymer molded cone predicted as a constant controlled drug release system by its slow bioresorbablity for medicating the infected tooth.

[0016] FIG. 2C is a diagram illustrating an exemplary arrangement of copolymer molded cone predicted as a constant controlled drug release system by its slow bioresorbablity resulting in effective control of the infection.

DETAIL DESCRIPTION

[0017] It is to be understood that the present disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The present disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. [0018] The use of "including", "comprising" or "having" and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. The terms "a" and "an" herein do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. Further, the use of terms "first", "second", and "third", and the like, herein do not denote any order, quantity, or importance, but rather are used to distinguish one element from another.

[0019] FIG. la is a diagram 100a illustrating a perspective view of cones molded with biocompatible and bioresorbable composition. According to non limiting preferred embodiment of the present disclosure, the diagram 100a including the ISO size cones 102a are molded with a copolymer blend of Poly-Lactic Acid and Poly-Glycolic Acid referred as PLGA to form a molded cone. 104a determines a medicated copolymer blend in form of cone. For convenience the present disclosure depicts only about two cones 102a molded with copolymer blend to form cone and medicated PLGA cone 104a. The International Organization for Standardization size cones 102a also referred as ISO size cones 102a used in the primary teeth and the medicated PLGA cone 104a is used in both primary and permanent teeth. However it should be understood that in general there may be any number of ISO sizes and accessory cones molded with copolymer blend to form a molded cones .Therefore the present disclosed cones molded with chemical composition are used for obturating and eradicating peri apical infection in tooth that may be included and/or supported by a system 100a consistent with the disclosed embodiments.

[0020] As shown in Figure la, the copolymer molded cone 104a is used for filling the root canal of infected tooth with medicated PLGA. The cone 104a molded with a copolymer composition can alter the degradation rate and mechanical properties of the obturating cone by changing the PLA-PGA ratio.

[0021] FIG. lb is a diagram 100b illustrating a perspective view of a cone inserted into the pulp canal of the primary tooth. According to non limiting preferred embodiment of the present disclosure, the diagram 100b including the cone 102b is molded with a copolymer blend of Poly-Lactic Acid and Poly-Glycolic Acid referred as PLGA. The molded cone 102b is then inserted into the pulp canal of the primary tooth 104b up to a reliable length of the tooth 106b. For convenience the present disclosure depicts only about a cone 102b molded with copolymer blend inserted into the pulp canal of the infected tooth 104b. However it should be understood that in general there may be any number of cones molded with copolymer blend inserted into any number of canals as similar as the cone 102b inserted into the pulp canal of the infected tooth 104b that may be included in the system. Therefore the present disclosed cones molded with chemical composition are used for obturating the pulp canal of the infected tooth that may be included and/or supported by a system 100b consistent with the disclosed embodiments.

[0022] As shown in Figure lb, the copolymer molded cone 102b is used for obturating the pulp canal of the infected tooth 104b. The cone 102b molded with PLGA composition is inserted into the root canal 106b up to reliable length of the infected tooth 104b. The cone 102b molded with PLGA composition gives a constant resorption rate with less inflammatory reactions.

[0023] FIG.2a is a diagram 200a illustrating a perspective view of a tooth infected with decay. According to non limiting preferred embodiment of the present disclosure, the diagram 200a including decay 204a is formed on the enamel of the tooth 202a. If the decay 204a is neglected at the earlier stage, then the decay 204a may spread to the bottom of the root canal 206a resulting damage to the tooth 202a. For convenience the present disclosure depicts only about a tooth 202a infected with decay 204a. However it should be understood that in general there may be any number of teeth that can be infected with decay as similar as the tooth 202a infected with the decay 204a that may be included in the system. Therefore the present disclosed tooth infected with decay that may be included and/or supported by a system 200a consistent with the disclosed embodiments.

[0024] As shown in Figure 2a, tooth 202a is infected with decay 204a which is further affecting the root canal 206a. If the development of the decay 204a is neglected at its earlier stage, then the decay 204a may spread to the bottom of the root canal 206a which may lead to periapical abscess 208a at the bottom of the effected root canal 206a.

[0025] FIG.2b is a diagram 200b illustrating a perspective view of an infected tooth medicated using a cone molded with blend of medicated copolymer material. According to non limiting preferred embodiment of the present disclosure, the diagram 200b including abscess 208b at the bottom of the effected root canal 206b is medicated using a cone 204b molded with the medicated copolymer blend. The copolymer is a composition of Poly-Lactic Acid and Poly-Glycolic Acid together with medicament. For convenience the present disclosure depicts only about an infected tooth 202b having abscess 208b is medicated using a cone 204b molded with the medicated copolymer blend. However it should be understood that in general there may be any number of teeth can be formed with abscess at the bottom of the root canal as similar as the infected tooth 202b formed with abscess 208b at the bottom of the root canal 206b that may be included in the system. Therefore the present disclosed tooth formed with abscess at the bottom of the root canal that may be included and/or supported by a system 200b consistent with the disclosed embodiments.

[0026] As shown in Figure 2b, the infected tooth 202b formed with abscess 208b at the bottom of the effected root canal 206b is medicated using a cone 204b molded with a medicated copolymer blend. The cone 204b is inserted into the root canal 206b up to a reliable length. The medicated copolymer blend molded to the cone 204b is then placed into the root canal 206b combats the bacterial contamination and reinfection in the infected tooth 202b. The insertion of cone 204b up to a reliable length is achieved using radiography. The proper operative assessment is achieved using visualization of Radio-opacity, radiographs and the like.

[0027] FIG.2c is a diagram 200c illustrating a perspective view of a medicated tooth 202c that is effected with decay and abscess. According to non limiting preferred embodiment of the present disclosure, the diagram 200c including the abscess at the bottom of the root canal 206 is cured after medicating with the cone 204c molded with the medicated copolymer composition. For convenience the present disclosure depicts about a medicated tooth 202c infected with decay and abscess using a cone 204c molded with medicated copolymer blend. However it should be understood that in general there may be any number of teeth can be medicated using a medicated ISO size cones moulded with copolymer blend as similar as the tooth 202c medicated using a cone 204c molded with copolymer blend that may be included in the system. Therefore the present disclosed teeth medicated with the cone that may be included are supported by a system 200c consistent with the disclosed embodiments.

[0028] As shown in the Figure.2c, tooth 202c is medicated using the cone 204c molded with medicated PLGA composition. The dental abscess is controlled using the medicated PLGA composition molded cone 204c. Cone 204c molded with medicated PLGA has the biocompatible and bioresorbable property which controls the drug released at constant rate resulting in effective control of the infection. The cone 204c because of bioresorbability degrades in vivo by hydrolysis into alpha hydroxyl acids that are metabolized by the body which further cannot result in unresorbtion.

[0029] Although the present invention has been described in terms of certain preferred embodiments and illustrations thereof, other embodiments and modifications to preferred embodiments may be possible that are within the principles and spirit of the invention. The above descriptions and figures are therefore to be regarded as illustrative and not restrictive.

[0030] Thus the scope of the present invention is defined by the appended claims and includes both combinations and sub combinations of the various features described herein above as well as variations and modifications thereof, which would occur to persons skilled in the art upon reading the foregoing description.

Claims

CLAIMS:

1. A saturation method of a drug for dental comprising: obturation of one or more pulp canals attained with a blend of copolymer composition comprising a Poly- Lactic Acid; and a Poly- Glycolic Acid; and inserting a plurality of non medicated PLGA cones into an infected canal of one or more tooth up to a reliable length, the cone incorporated with various medicaments used for constant controlled drug release system in one or more periapicalyinfected tooth.

2. The method of claim 1, comprising a step of inserting the cone molded with copolymer blend into an infected canal of a tooth.

3. The method of claim 1, comprising a step of inserting the cone molded with copolymer blend into an infected canal of a primary tooth.

4. The method of claim 1, comprising a step of inserting the medicated Poly- Lactic Acid; and a Poly- Glycolic Acid cone into an periapical infected tooth.

5. The method of claim 1, comprising a step of inserting the medicated Poly- Lactic Acid; and a Poly- Glycolic Acid cone into an periapical infected primary and permanent tooth.

6. The method of claim 1, comprising a step of metabolizing the copolymer composition with its biocompatible; and bioresorbable property.

7. The method of claim 6, comprising a step of attaining resorption by metabolism in vivo through hydrolysis into alpha hydraulic acids present within the body.

8. The method of claim 1, comprising a step of excluding a toxic effect of the cone to the apical tissue of the one or more tooth with the biocompatibility property of the copolymer composition.

9. The method of claim 1, comprising a step of inserting the cone of reliable length into a tooth attained using radiography.

10. The method of claim 1, comprising a step of exhibiting proper operative assessment visualization of Radio-opacity using radiographs.